MeiraGTx to Present at Upcoming Investor Conferences

LONDON and NEW YORK, Feb. 24, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., president and chief executive officer, will present at the Cowen and Company 40th Annual Health Care Conference in Boston on Monday, March 2, 2020 at 4:10 p.m. ET.

Dr. Forbes will also participate in a fireside chat at the Barclays Global Healthcare Conference in Miami on Thursday, March 12, 2020 at 9:00 a.m. ET.

A live webcast of each presentation will be available on the Investors page of the Company’s website at www.investors.meiragtx.com. A replay of the webcasts will be available for approximately 30 days following the presentations.

About MeiraGTxMeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.

For more information, please visit www.meiragtx.com.

Contacts

Investors:MeiraGTxElizabeth Broder(646) 860-7983[email protected] orMedia:W2O pureChristiana Pascale(212) 257-6722[email protected]

You May Also Be Interested In

• MeiraGTx to Participate in Upcoming Investor Conferences
• Orange: Combined Ordinary and Extraordinary Shareholders’ Meeting of 22 May 2024 Availability of documents
• Information relating to the total number of voting rights and shares making up the share capital at 26 April 2024 – post blocs acquisition by the Consortium